Bivomelagon

Search documents
Rhythm Pharmaceuticals (RYTM) Update / Briefing Transcript
2025-07-09 13:00
Rhythm Pharmaceuticals (RYTM) Update / Briefing July 09, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Top Line Results from Phase II Trial Evaluating Bivamilagon in Acquired Hypothalamic Obesity Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask the questions in the session, you will need to press 11 on your telephone. You will then hear an auto ...
Rhythm(RYTM) - 2025 Q1 - Earnings Call Transcript
2025-05-07 13:02
Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants David Connolly - Executive Director, Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, President & CEOJennifer Lee - Executive Vice President, Head of North AmericaYann Mazabraud - Executive VP & Head of InternationalHunter Smith - Chief Financial OfficerJon Wolleben - Managing DirectorTazeen Ahmad - MD - US Equity ResearchSeamus Fernandez - Senior Managing DirectorWhitney Ijem - Managing ...
Rhythm(RYTM) - 2025 Q1 - Earnings Call Transcript
2025-05-07 13:00
Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question and answer session. I would now like to hand the conference over to your speaker today, David Connolly, Investo ...